Navigating the US Food and Drug Administration (FDA) regulatory landscape is a critical step for any medical device company targeting the world’s largest MedTech market. While the FDA framework is well established, it is also highly structured, detail-driven, and unforgiving of missteps. For startups and SMEs, understanding how to position a device, select the right regulatory pathway, and engage effectively with the Agency can make the difference between a smooth clearance process and significant delays.
Our FDA consulting services are designed to provide clarity, direction, and hands-on support at every stage of the premarket journey. Our team have significant experience and have authored over thirty 510(k) submissions and led over eighty Q-Submission meetings. We help companies translate FDA requirements into practical regulatory strategies, align development decisions with submission expectations, and engage confidently with FDA reviewers. Whether you are pursuing a 510(k), preparing a De Novo request, or seeking early feedback through a Q-Submission, we work as an extension of your team to keep progress predictable and risk under control.
Correct FDA classification is the foundation of any successful medical device US regulatory pathway. We support clients in determining the appropriate device classification, product code, and regulation, including complex or borderline cases where multiple pathways may be possible. Our team assesses intended use, indications for use, technological characteristics, and risk profile to identify the most appropriate and least burdensome route to market.
Where classification is unclear, we prepare and manage 513(g) requests for information. This includes developing a clear regulatory position, drafting robust submission content, and interpreting FDA feedback to inform next steps. AWhen needed, a well-executed 513(g) can de-risk development, prevent misaligned submission strategies, and provide critical clarity early in the product lifecycle. We help ensure that these requests are targeted, efficient, and aligned with your broader commercial goals.
Early and effective engagement with the FDA can significantly improve submission outcomes. We support clients with the preparation and execution of Q-Submission (Pre-Sub) meetings, helping you obtain meaningful feedback on regulatory pathways, clinical strategies, non-clinical testing, and submission content before significant resources are committed.
Our team works closely with you to define clear meeting objectives, develop focused briefing packages, and craft precise questions that encourage actionable FDA responses. We also support meeting logistics, attendance, and follow-up, including interpretation of written feedback and alignment of internal teams on next steps. For startups and SMEs, this structured approach to FDA interaction can dramatically reduce regulatory uncertainty and prevent costly rework later in the process.
MD Compliance provides comprehensive support across FDA pre-market submissions, including traditional, abbreviated, and special 510(k)s, as well as De Novo requests. We support manufacturers from early planning through to submission and review, ensuring regulatory expectations are addressed clearly and efficiently.
Our services include gap assessments, submission strategy development, preparation and review of technical documentation, and support with FDA questions during review. We focus on producing clear, well-structured submissions that align device design, risk management, verification and validation, labelling, and clinical evidence — reducing review cycles and minimising the risk of additional information requests.
For Class III devices, the Premarket Approval (PMA) pathway represents the most rigorous FDA regulatory route, requiring extensive non-clinical, clinical, and manufacturing evidence. PMA submissions are highly scrutinised and closely linked to FDA inspections and ongoing compliance obligations.
MD Compliance supports manufacturers throughout the PMA process, including PMA strategy development, content planning, and preparation of submission modules. We assist in aligning clinical data, risk management, and quality system documentation to PMA expectations, and support FDA interactions during review. Our experience helps manufacturers manage the complexity of PMA submissions while maintaining regulatory clarity and momentum.
Clinical investigations conducted in the US for significant risk devices typically require an Investigational Device Exemption (IDE). The IDE process places strong emphasis on subject safety, study design, and compliance with FDA clinical and quality requirements.
MD Compliance supports clients with IDE strategy, preparation, and submission, including protocol development support, risk analysis, informed consent considerations, and regulatory documentation. We also assist manufacturers in responding to FDA feedback and maintaining compliance throughout the conduct of the investigation.
FDA inspections are a critical component of ongoing compliance and can occur at various stages of the device lifecycle. For PMA devices, manufacturers should expect pre-approval inspections (PAI) as part of the FDA’s assessment of manufacturing readiness and quality system implementation. In addition, the FDA conducts routine surveillance inspections to assess compliance with Quality System Regulation (QSR) requirements.
MD Compliance supports manufacturers in preparing for and managing FDA inspections, including PMA pre-approval inspections and routine FDA audits. Our services include inspection readiness assessments, mock inspections, documentation review, and practical coaching for inspection conduct. We also support manufacturers during and after inspections, including response to FDA observations and remediation planning. Our goal is to reduce inspection risk and support confident, effective engagement with FDA investigators.
